RxDoctor Payments Data

Angela Krull, MD

Physical Medicine & Rehabilitation · Sandy, UTNPI 1649377540

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,433 of the $3,980 with a category attached, or 86.3%. It is spread thinly across 42 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,043 and has fallen 65.2% since, to $363 in 2025.

$3,980in general payments, 2019–2025

Across 180 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$602
  • AbbVie$547
  • Boston Scientific$282
  • Collegium Pharmaceutical, Inc.$247
  • Pfizer$214
  • Teva Pharmaceuticals USA, Inc.$191
  • plus $2K from 36 others
$126,827in research payments, 2019–2025

Across 61 payments — averaging $2079.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$85K
  • Scilex Pharmaceuticals Inc.$35K
  • Boehringer Ingelheim International GmbH$4K
  • Seikagaku Corporation$2K

What the payments were for

  • Travel & lodging$54714%
  • Food & beverage$3,43386%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,980 in reported general payments places this provider in the 85th percentile of 117 physical medicine & rehabilitation providers in Utah.

See all physical medicine & rehabilitation providers in Utah

Medicare billing

Part B allowed, 2024
$26,907
Medicare patients
79
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen140$4,659
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen124$4,048
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$3,050
Oxycodone Hcl157$2,003
Gabapentin117$1,225
Fentanyl17$1,078
Buprenorphine Hcl29$937
Morphine Sulfate ErMorphine Sulfate33$748
Tramadol Hcl68$733
Morphine Sulfate16$431
Eszopiclone11$216
Tizanidine Hcl25$171
Meloxicam55$150
Cyclobenzaprine Hcl29$146
Celecoxib13$112

Paid to pharmacies, not to this prescriber.

Other physical medicine & rehabilitation in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →